Claims for Patent: 9,180,319

Summary for Patent: 9,180,319

Title:	Laser assisted periodontium and osseus regeneration protocol
Abstract:	A method of treating gum disease using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.5 to 1.2 watts, used with intermittent stops to control tissue temperature, to decontaminate the gum tissue and biostimulate the periodontium nonsurgically when used with a substrate, thus preventing the long junctional epithelium from migrating into the sulcus, preserving tissue height, and regenerating periodontium, the method comprising: placing the tip of the laser inside the sulcus; penetrating the entire sulcus by moving the laser light with intermittent stops to control tissue temperature vertically and horizontally throughout the sulcus; and placing a substrate in the sulcus prior to a blood clot forming, thus regenerating periodontium in the sulcus.
Inventor(s):	Kalmeta; Margaret V. (Aptos, CA)
Assignee:
Application Number:	13/864,226
Patent Claims:	1. A substrate mixture for the treatment of gum disease, wherein the substrate mixture is comprised of: a) a first substrate; and b) a second substrate, wherein the first substrate is comprised of: a) between 40% and 80% sterile water b) 1.1% sodium chloride; c) 1% benzoic acid; d) 9% lysine; e) 9% proline; f) 9% essential amino acids, wherein the essential amino acids include equal parts isoleucine, leucine, methionine, phenylalanine, threonine, tryptophan, valine and histadine; g) 2% non-essential amino acids, wherein the non-essential amino acids include equal parts alanine, arginine, glutamate, glycine and serine; h) 2% phosphates, wherein the phosphates include equal parts adenosine diphospate (ADP), adenosine triphosphate (ATP), and acetylcholine; and i) 6.9% free bases, wherein the free bases include equal parts adenosine, uridine, guanosine, and cytidine. 2. The substrate mixture of claim 1, wherein the second substrate is comprised of: a) tricalcium phosphate; and b) hydroxyapatite crystals. 3. The substrate mixture of claim 1, wherein the first substrate includes aspartate in an equal amount relative to the other non-essential amino acids. 4. The substrate mixture of claim 1, wherein the first substrate includes aspartate in a greater amount relative to the other non-essential amino acids. 5. The substrate mixture of claim 1, wherein the substrate mixture has a pH of about 7.4. 6. The substrate mixture of claim 2, wherein the tricalcium phosphate is precipitated in calcium hydroxide and devil's claw oil. 7. The substrate mixture of claim 2, wherein the hydroxyapatite crystals are precipitated in calcium hydroxide and devil's claw oil. 8. The substrate mixture of claim 2, wherein the tricalcium phosphate is in the form of crystals. 9. The substrate mixture of claim 8, wherein the tricalcium phosphate crystals are 10-50 micro meter in size. 10. The substrate mixture of claim 8, wherein the tricalcium phosphate crystals are 50-150 micro meter in size. 11. The substrate mixture of claim 8, wherein the tricalcium phosphate crystals are 100-300 micro meter in size. 12. The substrate mixture of claim 8, wherein the tricalcium phosphate crystals are 500-1000 micro meter in size. 13. The substrate mixture of claim 8, wherein the tricalcium phosphate crystals are 1-3 mm in size. 14. The substrate mixture of claim 2, wherein the hydroxyapatite crystals are non-porous. 15. The substrate mixture of claim 2, wherein the hydroxyapatite crystals are porous. 16. The substrate mixture of claim 8, wherein the tricalcium phosphate crystals are non-porous. 17. The substrate mixture of claim 8, wherein the tricalcium phosphate crystals are porous.

Details for Patent 9,180,319

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2031-04-01